Gene expression analysis of lung cancer

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 2, 2014, Pages 217-228

  Shi, W Y ^a   Liu, K D ^a   Xu, S G ^a   Zhang, J T ^a   Yu, L L ^a   Xu, K Q ^a   Zhang, T F ^a  

^a Dachang Hospital in Shanghai   (China)

Author keywords

Gene ontology; Lung cancer; microRNA; Pathway; Small molecules; Transcription factor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ATRACTYLOSIDE; CEFAMANDOLE; DNA; ENTINOSTAT; ILOPROST; MEBENDAZOLE; MICRORNA; MICRORNA 124A; MICRORNA 150; MICRORNA 196A; MICRORNA 196B; MICRORNA 200B; MICRORNA 200C; MICRORNA 203; MICRORNA 23A; MICRORNA 23B; MICRORNA 429; MICRORNA 96; NICLOSAMIDE; PHENOXYBENZAMINE; PROCHLORPERAZINE; PUROMYCIN; RAPAMYCIN; TANESPIMYCIN; THIORIDAZINE; TRICHOSTATIN A; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; VORINOSTAT; MIRN196 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN; TRANSCRIPTOME;

ARTICLE; CANCER GENETICS; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPLICATION; DNA TRANSCRIPTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE NUMBER; GENE ONTOLOGY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LUNG CANCER; MISMATCH REPAIR; PROTEIN BINDING; RNA STABILITY; CELL CYCLE; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; PROCEDURES; TUMOR CELL LINE;

CELL CYCLE; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; TRANSCRIPTOME;

EID: 84896920411     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. STERNER-KOCK A, THOREY IS, KOLI K, WEMPE F, OTTE J, BANGSOW T, KUHLMEIER K, KIRCHNER T, JIN S, KESKI-OJA J, VON MELCHNER H. Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev 2002; 16: 2264-2273.
2. DANG SP, LIBERMAN BA, SHEPHERD FA, MESSNER H, TWEEDDALE M, GARDNER HA, COLGAN T, ROSE TH, EVANS WK. Therapy-related leukemia and myelodysplasia in small-cell lung cancer. Report of a case and results of morphologic, cytogenetic, and bone marrow culture studies in long-term survivors. Arch Intern Med 1986; 146: 1689-1694.
3. COLLINS LG, HAINES C, PERKEL R, ENCK RE. Lung cancer: diagnosis and management. Am Fam Phys 2007; 75: 56-63.
4. FERLAY J, SHIN HR, BRAY F, FORMAN D, MATHERS C, PARKIN DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
5. URGARD E, VOODER T, VÕSA U, VÄLK K, LIU M, LUO C, HOTI F, ROOSIPUU R, ANNILO T, LAINE J, FRENZ CM, ZHANG L, METSPALU A. Metagenes associated with survival in non-small cell lung cancer. Cancer Inform 2011; 10: 175-183.
6. OH JJ, TASCHEREAU EO, KOEGEL AK, GINTHER CL, ROTOW JK, ISFAHANI KZ, SLAMON DJ. RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. Lung Cancer 2010; 70: 253-262.
7. KALARI S, JUNG M, KERNSTINE KH, TAKAHASHI T, PFEIFER GP. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene 2013; 32: 3559-3568.
8. HELMAN E, NAXEROVA K, KOHANE IS. DNA hypermethylation in lung cancer is targeted at differentiation-associated genes. Oncogene 2012; 31: 1181-1188.
9. WEI S, WANG LE, MCHUGH MK, HAN Y, XIONG M, AMOS CI, SPITZ MR, WEI QW. Genome-wide geneenvironment interaction analysis for asbestos ex-posure in lung cancer susceptibility. Carcinogenesis 2012; 33: 1531-1537.
10. OCAK S, YAMASHITA H, UDYAVAR AR, MILLER AN, GONZALEZ AL, ZOU Y, JIANG A, YI Y, SHYR Y, ESTRADA L, QUARANTA V, MASSION PP. DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene 2010; 29: 6331-6342.
11. DONNEM T, FENTON CG, LONVIK K, BERG T, EKLO K, ANDERSEN S, STENVOLD H, AL-SHIBLI K, AL-SAAD S, BREMNES RM, BUSUND LT. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One 2012; 7: e29671.
12. GAO W, XU J, LIU L, SHEN H, ZENG H, SHU Y. A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother 2012; 66: 21-28.
13. LAMB J, CRAWFORD ED, PECK D, MODELL JW, BLAT IC, WROBEL MJ, LERNER J, BRUNET JP, SUBRAMANIAN A, ROSS KN, REICH M, HIERONYMUS H, WEI G, ARMSTRONG SA, HAGGARTY SJ, CLEMONS PA, WEI R, CARR SA, LANDER ES, GOLUB TR. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
14. PACINI C, IORIO F, GONÇALVES E, ISKAR M, KLABUNDE T, BORK P, SAEZ-RODRIGUEZ J. DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data. Bioinformatics 2013; 29: 132-134.
15. YEH CT, WU AT, CHANG PM, CHEN KY, YANG CN, YANG SC, HO CC, CHEN CC, KUO YL, LEE PY, LIU YW, YEN CC, HSIAO M, LU PJ, LAI JM, WANG LS, WU CH, CHIOU JF, YANG PC, HUANG CY. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med 2012; 186: 1180-1188.
16. CHEN MH, LIN KJ, YANG WL, KAO YW, CHEN TW, CHAO SC, CHANG PM, LIU CY, TZENG CH, CHAO Y, CHEN MH, YEH CN, HUANG CY. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer 2013; 119: 293-303.
17. WILLIAMS G. A searchable cross-platform gene expression database reveals connections between drug treatments and disease. BMC Genomics 2012; 13; 12 doi: 10.1186/1471-2167-13-12.
18. CLAERHOUT S, LIM JY, CHOI W, PARK YY, KIM K, KIM SB, LEE JS, MILLS GB, CHO JY. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 2011; 6(9): e24662.
19. LAURILA K, LAHDESMAKI H. Systematic analysis of disease-related regulatory mutation classes reveals distinct effects on transcription factor binding. In Silico Biol 2009; 9: 209-224.
20. WITTWER J, MARTI-JAUN J, HERSBERGER M. Functional polymorphism in ALOX15 results in increased allele-specific transcription in macrophages through binding of the transcription factor SPI1. Hum Mutat 2006; 27: 78-87.
21. MATSUDA M, SAKAMOTO N, FUKUMAKI Y. Delta-thalassemia caused by disruption of the site for an erythroid-specific transcription factor, GATA-1, in the delta-globin gene promoter. Blood 1992; 80: 1347-1351.
22. CHOWDHARY R, TAN SL, PAVESI G, JIN J, DONG D, MATHUR SK, BURKART A, NARANG V, GLURICH I, RABY BA, WEISS ST, WONG L, LIU JS, BAJIC VB. A database of annotated promoters of genes associated with common respiratory and related diseases. Am J Respir Cell Mol Biol; 47: 112-119.
23. WANG G, MAO W, ZHENG S. MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett 2008; 582: 3663-3668.
24. DU L, SCHAGEMAN JJ, SUBAUSTE MC, SABER B, HAMMOND SM, PRUDKIN L, WISTUBA II, JI L, ROTH JA, MINNA JD, PERTSEMLIDIS A. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009; 7: 1234-1243.
25. SEIKE M, GOTO A, OKANO T, BOWMAN ED, SCHETTER AJ, HORIKAWA I, MATHE EA, JEN J, YANG P, SUGIMURA H, GEMMA A, KUDOH S, CROCE CM, HARRIS CC. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 2009; 106: 12085-12090.
26. HERNANDEZ MR, AGAPOVA OA, YANG P, SALVADOR-SILVA M, RICARD CS, AOI S. Differential gene expression in astrocytes from human normal and glaucomatous optic nerve head analyzed by cDNA microarray. Glia 2002; 38: 45-64.
27. DAVIS S, MELTZER PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and Bio-Conductor. Bioinformatics 2007; 23: 1846-1847.
28. SMYTH GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: N. 1, Article 3.
29. ASHBURNER M, BALL CA, BLAKE JA, BOTSTEIN D, BUTLER H, CHERRY JM, DAVIS AP, DOLINSKI K, DWIGHT SS, EPPIG JT, HARRIS MA, HILL DP, ISSEL-TARVER L, KASARSKIS A, LEWIS S, MATESE JC, RICHARDSON JE, RINGWALD M, RUBIN GM, SHERLOCK G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29.
30. ZHENG Q WANG XJ. GOEAST: a web-based software toolkit for Gene Ontology enrichment analysis. Nucleic Acids Res 2008; 36(Web Server issue): W358-363.
31. ZHANG B, KIROV S, SNODDY J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005; 33(Web Server issue): W741-748.
32. DEXTER DUNCAN NPABZ. WebGestalt2: an updated and expanded version of the Web-based Gene Set Analysis Toolkit. BMC Bioinformatics 2010; Suppl 4: 10.
33. BENJAMINI Y, HOCHBERG Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B 1995; 57: 289-300.
34. SMYTHE WR, WILLIAMS JP, WHEELOCK MJ, JOHNSON KR, KAISER LR, ALBELDA SM. Cadherin and catenin expression in normal human bronchial epithelium and non-small cell lung cancer. Lung Cancer 1999; 24: 157-168.
35. KORT EJ, PANETH N, VANDE WOUDE GF. The decline in U.S. cancer mortality in people born since 1925. Cancer Res 2009; 69: 6500-6505.
36. TAKAHASHI Y, FORREST AR, MAENO E, HASHIMOTO T, DAUB CO, YASUDA J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 2009; 4: e6677.
37. ZHANG F, CHEN JY. Discovery of pathway biomarkers from coupled proteomics and systems biology methods. BMC Genomics 2010; 11 Suppl 2: S12.
38. LEYSEN JE, W GOMMEREN, L HEYLEN, WH LUYTEN, I VAN DE WEYER, P VANHOENACKER, G HAEGEMAN, A SCHOTTE, P VAN GOMPEL, R WOUTERS, AS LESAGE. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 1996; 50: 1567-1580.
39. CHAO SK, J LIN, J BROUWER-VISSER, AB SMITH, 3RD, SB HORWITZ, HM MCDAID. Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent. Proc Natl Acad Sci U S A 2011; 108: 391-396.
40. LIAO WT, X WANG, LH XU, QL KONG, CP YU, MZ LI, L SHI, MS ZENG, LB SONG. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer 2009; 115: 1507-1517.
41. HAYAMA S, Y DAIGO, T KATO, N ISHIKAWA, T YAMABUKI, M MIYAMOTO, T ITO, E TSUCHIYA, S KONDO, Y NAKAMURA. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006; 66: 10339-10348.
42. HANSEN LT, T THYKJAER, TF ORNTOFT, LJ RASMUSSEN, P KELLER, M SPANG-THOMSEN, TB Edmonston, C Schmutte, R Fishel, LN Petersen. The role of mismatch repair in small-cell lung cancer cells. Eur J Cancer 2003; 39: 1456-1467.
43. DOGRA N, T MUKHOPADHYAY. Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication. J Biol Chem 2012; 287: 30625-30640.
44. XU L, L SU, X LIU. PKCdelta regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells. Mol Cancer Ther 2012; 11: 2174-2182.
45. MEINERS S, O EICKELBERG. What shall we do with the damaged proteins in lung disease? Ask the proteasome! Eur Respir J 2012; 40: 1260-1268.
46. LI Y, Z SUN, JM CUNNINGHAM, MC AUBRY, JA WAMPFLER, GA CROGHAN, C JOHNSON, D WU, JA AAKRE, J MOLINA, L WANG, VS PANKRATZ, P YANG. Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy. Clin Cancer Res 2011; 17: 3830-3840.
47. KASTNER S, T VOSS, S KEUERLEBER, C GLOCKEL, M FREISSMUTH, W SOMMERGRUBER. Expression of G protein-coupled receptor 19 in human lung cancer cells is triggered by entry into S-phase and supports G(2)-m cell-cycle progression. Mol Cancer Res 2012; 10: 1343-1358.
48. MENG X, P LU, H BAI, P XIAO, Q FAN. Transcriptional regulatory networks in human lung adenocarcinoma. Mol Med Report 2012; 6: 961-966.
49. ZHAN X, W WU, B HAN, G GAO, R QIAO, J LV, S ZHANG, W ZHANG, W FAN, H CHEN, T ZHANG, A GU, J SHEN, Q WU, D LU. Hsa-miR-196a2 Functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a chinese population. J Clin Lab Anal 2012; 26: 441-446.
50. HURTEAU GJ, JA CARLSON, SD SPIVACK, GJ BROCK. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007; 67: 7972-7976.
51. DRAGNEV K, M YOU, Y WANG, R LUBET. Lung cancer chemoprevention: difficulties, promise and potential agents? Expert Opin Investig Drugs 2013; 22: 35-47.
52. KHURI FR. The dawn of a revolution in personalized lung cancer prevention. Cancer Prev Res (Phila) 2011; 4: 949-953.
53. SZABO E. Altered histology provides a positive clinical signal in the bronchial epithelium. Cancer Prev Res (Phila) 2011; 4: 775-778.
54. PEHLIVAN Y, IH TURKBEYLER, O BALAKAN, A SEVINC, M YILMAZ, K BAKIR, AM ONAt. Possible anti-metastatic effect of iloprost in a patient with systemic sclerosis with lung cancer: a case study. Rheumatol Int 2012; 32: 1437-1441.
55. TENNIS MA, M VAN SCOYK, LE HEASLEY, K VANDERVEST, M WEISER-EVANS, S FREEMAN, RL KEITH, P SIMPSON, RA NEMENOFF, RA WINN. Prostacyclin inhibits nonsmall cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia 2010; 12: 244-253.
56. NAGATHIHALLI NS, PP MASSION, AL GONZALEZ, P LU, PK DATTA. Smoking induces epithelial-to-Mesenchymal Transition in Non-Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin. Mol Cancer Ther 2012; 11: 2362-2372.
57. SUDA K, K TOMIZAWA, M FUJII, H MURAKAMI, H OSADA, Y MAEHARA, Y YATABE, Y SEKIDO, T MITSUDOMI. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2011; 6: 1152-1161.
58. KAKIHANA M, T OHIRA, D CHAN, RB WEBSTER, H KATO, HA DRABKIN, RM GEMMILL. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol 2009; 4: 1455-1465.
59. NIESEN MI, G BLANCK. Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull 2009; 32: 480-482.
60. HURTUBISE A, ML BERNSTEIN, RL MOMPARLER. Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int 2008; 8: 16.